Muutke küpsiste eelistusi

Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation ILLUSTRATE

  • Formaat: 122 pages, kõrgus x laius x paksus: 2312x1500x0.50 mm, kaal: 600 g
  • Sari: ACTA Biomedica Lovaniensia
  • Ilmumisaeg: 01-Nov-2003
  • Kirjastus: Coronet Books Inc
  • ISBN-10: 9058673278
  • ISBN-13: 9789058673275
Teised raamatud teemal:
Drug Eluting Stents: Anti-Inflammatory Approach To Prevent Restenosis After Stent Implantation ILLUSTRATESuurem pilt
  • Formaat: 122 pages, kõrgus x laius x paksus: 2312x1500x0.50 mm, kaal: 600 g
  • Sari: ACTA Biomedica Lovaniensia
  • Ilmumisaeg: 01-Nov-2003
  • Kirjastus: Coronet Books Inc
  • ISBN-10: 9058673278
  • ISBN-13: 9789058673275
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9789058673275.html
General Introduction
1(10)
Role of inflammation in the pathogenesis of restenosis
1(5)
Local drug delivery using drug eluting stents
6(5)
Materials and Methods
11(4)
Stent and stent coating
11(1)
In vitro drug release evaluation
11(1)
In vivo stent implantation
11(2)
Quantitative coronary angiography
11(1)
Histopathology and morphometry
12(1)
Immunohistochemistry staining
13(1)
Scanning electron microscopy (SEM)
13(1)
Statistics
13(2)
Optimalisation of Local Methylprednisolone Delivery to Inhibit Inflammatory Reaction and Neointimal Hyperplasia of Coated Coronary Stents
15(16)
Introduction
15(1)
Materials and Methods
16(3)
Stents and stent coating
16(1)
In vitro drug release
16(1)
Quantitative coronary angiography
17(1)
Histopathology and morphometry
17(1)
Scanning electron microscopy (SEM)
18(1)
Results
19(7)
SEM images of the coated stents
19(1)
In vitro drug release
20(1)
SEM evaluation of stented artery
21(1)
In vivo studies
22(1)
Quantitative coronary angiography
22(1)
Histopathology
22(1)
Morphometry
23(3)
Discussion
26(5)
Cytochalasin D Polymer Coated Stents Reduce Neointimal Formation in a Porcine Coronary Model
31(16)
Introduction
31(1)
Materials and Methods
32(3)
Polymer and drug coated stents
32(1)
In vitro pharmacokinetics of drug coated stents
32(1)
In vivo pharmacokinetics of drug coated stents and systemic toxicity evaluation
32(1)
Efficacy of cytochalasin D coated stents on neointimal hyperplasia
33(1)
Quantitative coronary angiography
33(1)
Histopathology and morphometry
34(1)
Immunohistochemistry staining
35(1)
Scanning electron microscopy (SEM)
35(1)
Results
35(7)
In vitro pharmacokinetics
35(1)
In vivo pharmacokinetics and systemic toxicity evaluation
36(1)
Efficacy of cytochalasin D coated stents on neointimal hyperplasia
36(1)
Quantitative coronary angiographic analysis
37(1)
Morphometric and histopathologic evaluation
37(5)
Discussion
42(5)
Long-Term Biocompatibility Evaluation of a Biodegradable Polymer Coated Stent in a Porcine Coronary Stent Model
47(16)
Introduction
47(1)
Materials and Methods
48(3)
Stent and stent coating
48(1)
Stent implantation
48(1)
Acute Study
48(1)
Chronic Study
48(1)
Quantitative coronary angiography
49(1)
Histopathology and morphometry
49(1)
Scanning electron microscopy (SEM)
50(1)
Results
51(7)
SEM evaluation of stented artery
51(1)
Quantitative coronary angiography
51(1)
Histopathology
52(2)
Morphometry
54(4)
Discussion
58(5)
Methotrexate Loaded Sae-Coated Coronary Stents Reduce Neointimal Hyperplasia in a Porcine Coronary Model
63(14)
Introduction
63(1)
Materials and Methods
64(3)
Stent and stent coating
64(1)
In vitro methotrexate release kinetics
64(1)
Impact of methotrexate on vascular smooth muscle cell (SMC) in vitro
64(1)
SMC proliferation assay
64(1)
Effects on SMC viability
65(1)
Stent implantation
65(1)
Biocompatibility of the coated stents
65(1)
Methotrexate coated stents
66(1)
Histopathology and morphometry
66(1)
Results
67(6)
Images of the coated stents
67(1)
In vitro methotrexate release kinetics
67(1)
Effect of methotrexate on SMC proliferation and viability
68(1)
In vivo biocompatibility of SAE coated stents
69(1)
In vivo effect of stent-based methotrexate delivery on neointimal formation
70(3)
Discussion
73(4)
Local Methylprednisolone Delivery Using a Biodivysio Phosphorylcholine Coated Drug Delivery Stents Reduces Inflammation and Neointimal Hyperplasia in a Porcine Coronary Stent Model
77(10)
Introduction
77(1)
Materials and Methods
78(2)
Phosphorylcholine (PC) coated stents
78(1)
In vitro drug release
78(1)
Stent implantation
78(1)
Acute study
78(1)
Chronic study
78(1)
Quantitative coronary angiography
78(1)
Histopathology and morphometry
79(1)
Results
80(3)
In vitro drug release
80(1)
In vivo studies
80(1)
Quantitative coronary angiography
81(1)
Histopathology
81(1)
Morphometry
82(1)
Discussion
83(4)
Stent Based Dexamethasone Delivery: From Pre-Clinical Data to the Stride Trial
87(12)
Introduction
87(1)
Materials and Methods
88(3)
The dexamethasone loaded BiodivYsio matrix Lo stent
88(1)
Patient population
89(1)
Procedure
89(1)
Quantitative coronary angiographic analysis
90(1)
Clinical follow-up
91(1)
Study end points and statistics
91(1)
Results
91(5)
In hospital results, 30 days and six months major adverse coronary events
92(1)
Angiographic results
92(1)
Angiographic results in stable and unstable angina patients
93(3)
Discussion
96(3)
General Discussion and Conclusions 99(4)
References 103(16)
Publications 119